Physician profile
Randolph Ross
NPI 1518076157
$2,269.63
in general payments reported to CMS, 2019-2025
27 companies · $202 in 2025
The $202 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $997 · 2020: $179 · 2021: $355 · 2022: $236 · 2023: $146 · 2024: $153 · 2025: $202.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $501.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $501.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $306.95 | 2023-2025 | Trelegy Ellipta |
| Neotract INC. | $266.10 | 2019-2020 | |
| Astellas Pharma US INC | $264.46 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $167.94 | 2019-2023 | |
| Janssen Biotech, INC. | $153.74 | 2019-2022 | |
| Coloplast Corp | $148.12 | 2019-2022 | |
| Myriad Genetic Laboratories, INC. | $114.97 | 2021-2022 | |
| Pfizer INC. | $97.64 | 2019-2021 | |
| Boston Scientific Corporation | $89.47 | 2019 | |
| Cook Medical LLC | $86.00 | 2019-2021 | |
| Teleflex LLC | $85.52 | 2021 | |
| Allergan, INC. | $72.78 | 2019-2021 | |
| Viatris Specialty LLC | $64.01 | 2025 | Yupelri |
| Dendreon Pharmaceuticals LLC | $63.24 | 2019-2020 | |
| Tolmar Pharmaceuticals, INC. | $63.07 | 2019-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $34.77 | 2025 | Sunosi |
| Amgen INC. | $25.58 | 2019 | |
| Rochester Medical Corporation | $24.26 | 2019 | |
| Blue Earth Diagnostics | $23.12 | 2019 | |
| Olympus America INC. | $18.14 | 2021 | |
| Ambu INC. | $17.30 | 2021 | |
| Axonics, INC. | $16.07 | 2021 | |
| Urogen Pharma, INC. | $14.79 | 2021 | |
| Urovant Sciences INC | $14.51 | 2022 | |
| Mallinckrodt Enterprises LLC | $13.02 | 2019 | |
| Travere Therapeutics, INC. | $12.56 | 2019 | |
| Sagent Pharmaceuticals | $11.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randolph Ross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.